一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Enhanced Collagen Prolyl 4-Hydroxylase Activity and Expression Promote Cancer Progression via Both Canonical and Non-Canonical Mechanisms.
Enhanced Collagen Prolyl 4-Hydroxylase Activity and Expression Promote Cancer Progression via Both Canonical and Non-Canonical Mechanisms.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胶原蛋白是细胞外基质(ECM)的主要组成成分;在癌症中,肿瘤细胞和肿瘤微环境(TME)中的基质细胞常会异常分泌胶原蛋白。胶原脯氨酰4-羟化酶(C-P4H)可在胶原蛋白三肽基序-X-Y-Gly中的Y位将脯氨酸羟化为4-羟脯氨酸,对成熟胶原三聚体的稳定和胶原分泌至关重要。本综述总结C-P4H的结构与功能、C-P4H酶活性的调控,以及其α亚基P4HA1过表达在促进癌症进展中的作用,并讨论P4HA1作为预后标志物和治疗靶点的潜力。P4HA1几乎在所有实体瘤中均有过表达,包括乳腺癌、结直肠癌和肺癌,并与癌症进展、治疗应答较差和患者生存较短相关。对P4HA1过表达的特征分析显示,其不仅通过经典的胶原沉积作用,还通过细胞干性、缺氧反应、葡萄糖代谢、血管生成和调节TIL(肿瘤浸润淋巴细胞)等非经典功能,与癌症的关键特征相关。
因此,P4HA1是有吸引力的治疗靶点,有望用于开发新型靶向疗法,改善多种癌症的治疗应答。
Collagens make up the main components of the extracellular matrix (ECM), and, in cancer, are often aberrantly secreted by both tumor cells and stromal cells in the tumor microenvironment (TME). Collagen prolyl 4-hydroxylase (C-P4H), an enzyme that hydroxylates proline into 4-hydroxyproline at the Y position of the collagen -X-Y-Gly- triplet motif, is essential for the stability of the mature collagen trimer and collagen secretion. In this review, we summarize the research on the structure and function of C-P4H, the regulation of C-P4H enzyme activity, and the role of overexpression of its α-subunit, P4HA1, in promoting cancer progression as well as its potential as a prognostic marker and therapeutic target.
Overexpression of P4HA1 is displayed in almost all solid cancers, including breast, colorectal, and lung cancer, and is associated with cancer progression, worse response to therapy, and poorer patient survival.
Characterization of P4HA1 overexpression has demonstrated links to key hallmarks of cancer, not only in the canonical collagen deposition role, but also in non-canonical functions, such as cell stemness, hypoxic response, glucose metabolism, angiogenesis, and modulation of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment. P4HA1 is thus an attractive target for developing novel targeted therapies to improve treatment response in many cancer types.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。